NP-G2-044

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

About Novita Pharmaceuticals

Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.

Therapeutic Areas